Recombinant Human IGF-BP3 protein

Background

Insulin-like Growth Factor-Binding Protein 3 (IGF-BP3) belongs to the IGFBP family, which are all cysteinerich proteins with conserved cysteine and have an IGFBP domain and a thyroglobulin type-I domain. Mature human IGF-BP3 contains 264 a.a. with three potential N-linked and two potential O-linked glycosylation sites. It is expressed by most tissues and has higher levels during extrauterine life and peak during puberty. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. The protein forms a ternary complex with IGF-I or II and acid-labile subunit. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Decreased plasma levels of IGF-BP3 often happen during the progression of prostate cancer from benign to metastatic disease.

Expression system

Escherichia coli.

Purity

> 98 % by SDS-PAGE and HPLC analyses.

Endotoxin

Less than 1 EU/μg of rHuIGF-BP3 as determined by LAL method.

Form

Sterile Filtered White lyophilized (freeze-dried) powder. Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Packaging image shown for reference. Select a size from the available options.